Burela Alejandra, Hernández-Vásquez Akram, Comandé Daniel, Peralta Verónica, Fiestas Fabian
Instituto de Evaluación de Tecnologías en Salud e Investigación - IETSI, EsSalud, Lima, Perú.
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina.
Rev Peru Med Exp Salud Publica. 2020 Oct-Dec;37(4):605-610. doi: 10.17843/rpmesp.2020.374.6330. Epub 2021 Feb 3.
To systematically review the effectiveness and safety of chlorine dioxide solution and chlorine derivatives used in the prevention or treatment of COVID-19.
This review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and follows the guidelines provided in the Cochrane Handbook for Systematic Reviews of Interventions. A librarian developed and executed the search strategy; it was further reviewed by two of the authors and complemented by manual search. Randomized clinical trials, quasi-experimental studies, cohort studies, case-control studies, cross-sectional studies, and case reports were included; in vitro or animal studies were excluded. Abstract and full-text screening according to pre-defined eligibility criteria were performed by two reviewers independently using web application Rayyan QCRI. Disagreements on study selection were resolved by a third reviewer. The systematic review protocol was registered in PROSPERO (CRD42020200641).
Neither published nor pre-print studies evaluating the use of chlorine dioxide or derivatives on SARS-CoV-2 infection were identified. The only finding was an unpublished observational study registry which has no results released yet.
To date, there are no scientific evidence to uphold the use of chlorine dioxide or derivatives as preventive or therapeutic agents against COVID-19.
系统评价二氧化氯溶液和氯衍生物在预防或治疗新型冠状病毒肺炎（COVID-19）中的有效性和安全性。
本综述遵循系统评价和Meta分析的首选报告项目（PRISMA），并遵循Cochrane干预措施系统评价手册中提供的指南。由一名图书馆员制定并执行检索策略；两名作者进一步对其进行了审查，并通过手工检索进行补充。纳入随机临床试验、准实验研究、队列研究、病例对照研究、横断面研究和病例报告；排除体外或动物研究。两名评价员使用网络应用程序Rayyan QCRI根据预先定义的纳入标准独立进行摘要和全文筛选。研究选择方面的分歧由第三名评价员解决。该系统评价方案已在国际前瞻性系统评价注册库（PROSPERO）中注册（注册号：CRD42020200641）。
未检索到已发表或预印本研究中评估二氧化氯或其衍生物用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的情况。唯一的发现是一项未发表的观察性研究登记，目前尚未公布结果。
迄今为止，尚无科学证据支持使用二氧化氯或其衍生物作为预防或治疗COVID-19的药物。
